More forecasts: Atlanta 30 day forecast
Menlo Park Biotech Hexagon Bio Lands $62M to Push Cancer Drug to Trials
Oct 26, 2026
Hexagon Bio's HEX-360 targets HER2-positive tumors and uses a payload designed to address resistance associated with approved ADC payloads — human trials could start in 2027.












